Expand PHVS Menu
PHVS MENU

PHVS Latest Press Releases

-- August 12, 2026 --

Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update Globe Newswire 6:50 AM

-- August 6, 2026 --

Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology Globe Newswire 6:50 AM

-- July 22, 2026 --

Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema Globe Newswire 6:50 AM

-- July 6, 2026 --

Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks Globe Newswire 6:50 AM

-- June 15, 2026 --

Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026 Globe Newswire 6:50 AM

-- June 11, 2026 --

Pharvaris Announces Annual General Meeting of Shareholders Globe Newswire 6:50 AM

-- May 29, 2026 --

Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026 Globe Newswire 6:50 AM

-- May 12, 2026 --

Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update Globe Newswire 4:05 PM

-- May 11, 2026 --

Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares Globe Newswire 4:15 PM

-- May 8, 2026 --

Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares Globe Newswire 6:00 AM

-- April 20, 2026 --

Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference Globe Newswire 6:50 AM

-- April 2, 2026 --

Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Globe Newswire 6:50 AM

-- March 20, 2026 --

Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology Globe Newswire 6:50 AM
Market Data Delayed 15 Minutes